chartexchange

ANVS
Annovis Bio, Inc.
stockNYSE

At CloseNov 13, 2026 3:54:35 PM EST
0.91USD+7.271%(+0.06)2,197,306
Pre-marketNov 13, 2026 9:06:30 AM EST
0.8718USD+2.904%(+0.0246)
After-hoursNov 13, 2026 4:18:30 PM EST
0.94USD+3.433%(+0.03)
Loading…
Loading…
Healthcare
Biotechnology
HQ
Berwyn, PA, USA
Previous Close
$0.85
Beta
2.38
52-Week High
$5.50 2025-11-28
52-Week Low
$0.62 2026-11-05
SMA 50
$1.11
SMA 200
$1.82
Avg. Vol 10D
5.89M
Avg. Vol 30D
2.41M
Avg. Vol 90D
1.41M
Relative Vol
0.91
37.65M
1.9000%
1,500,000
18,312
ANVS Profile

annovis bio, inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. its lead compound is anvs401, which is in phase 2a clinical trials for the treatment of alzheimer's disease (ad), parkinson's disease, alzheimer's disease in down syndrome, and other chronic neurodegenerative disorders. the company is also developing anvs405 for protecting the brain after traumatic brain injury and/or stroke; and anvs301, which is in phase i clinical trials to increase cognitive capability in later stages of ad and dementia. annovis bio, inc. was founded in 2008 and is based in berwyn, pennsylvania.

ANVS Performance
PeriodPriceDateChangeBeta
1W0.842026-11-06+9.13%2.510
1M1.062026-10-13-13.02%5.959
3M1.792026-08-13-48.49%4.503
6M2.222026-05-13-58.47%3.111
1Y2.292025-11-13-59.74%2.384
2Y7.412024-11-13-87.56%—
5Y30.012021-11-12-96.93%1.602
ANVS Stock Summary

Annovis Bio, Inc. (NYSE:ANVS) stock price today is $0.92, and today's volume is 2,197,306. ANVS is up 8.829% today. The 30 day average volume is 2.41M. ANVS market cap is $39.67M with 43.02M shares outstanding.